 DURHAM, NC ACCESSWIRE January 19, 2021 Heat Biologics, Inc. Heat NASDAQ:HTBX, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ZVX-60 to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19. Jeff Wolf, Heats CEO, commented, Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials. 